Lithium alters regional rat brain myo-inositol at 2 and 4 weeks: An ex-vivo magnetic resonance spectroscopy study at 18.8 T

NeuroReport

Volumn 17, Issue 12, 2006, Pages 1323-1326

  McGrath, Brent M ^a,b   Greenshaw, Andrew J ^a   McKay, Ryan ^a   Slupsky, Carolyn M ^a   Silverstone, Peter H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Animalmodels; Bipolar disorder; Brain changes; Inositol depletion; Lithium; Mood stabilizers; Regional magnetic resonance spectroscopy

Indexed keywords

INOSITOL; LITHIUM; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; HIPPOCAMPUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TEMPORAL CORTEX;

ANIMALS; ANTIMANIC AGENTS; BRAIN; BRAIN CHEMISTRY; DRUG ADMINISTRATION SCHEDULE; INOSITOL; LITHIUM CHLORIDE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 33748353819     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000230501.40349.41     Document Type: Article

References (25)

1. Fieve RR. Lithium therapy at the millennium: a revolutionary drug used for 50 years faces competing options and possible demise. Bipolar Disord 1999; 1:67-70.
2. Post RM, Weiss SRB, Clark M, Chuang D, Hough C, Li H. Lithium, carbamazepine, and valproate in affective illness. In: Manji H, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanisms of action. Washington: American Psychiatric Press Inc.; 2000. pp. 219-248.
3. Baldassano CF, Datto SM, Littman L, Lipari MA. What drugs are best for bipolar depression? Ann Clin Psychiatry 2003; 15:225-232.
4. O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 2000; 880:84-91.
5. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat N Biol 1971; 233:267-268.
6. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982; 206:587-595.
7. Berridge MJ, Irvine RF. Inositol phosphates and cell signaling. Nature 1989; 341:197-205.
8. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992; 58:18-38.
9. Belmaker RH, Agam G, van Calker D, Richards MH, Kofman O. Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on PI cycle: depletion by chronic lithium of brain inositol is specific to hypothalamus, and inositol levels may be abnormal in postmortem brain from bipolar patients. Neuropsychopharmacology 1998; 19:220-232.
10. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417:292-295.
11. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum Psychopharmacol Clin Exp 2002; 17:321-327.
12. Ramaprasad S. Lithium spectroscopy imaging of rat brain at therapeutic doses. Magn Reson Imaging 2004; 22:727-734.
13. Ghoshdastidar D, Dutta RN, Poddar MK. In vivo distribution of lithium in plasma and brain. Ind J Exp Biol 1989; 27:950-954.
14. Pellegrino LJ, Pellegrino AS, Cushman AJ. A stereotaxic atlas of the rat brain. New York: Plenum Press; 1979.
15. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-917.
16. Markley JL, Bax A, Arata Y, Hilbers CW, Kaptein R, Sykes BD, et al. Recommendations for the presentation of NMR structures of proteins and nucleic acids. IUPAC-IUBMB-IUPAB inter-union task group on the standardization of data bases of protein and nucleic acid structures determined by NMR spectroscopy. J Biomol NMR 1998; 12:1-23.
17. Revicki DA, Hirschfeld RM, Ahearn EP, Weisler RH, Palmer C, Keck PE Jr. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trail. J Affect Disord 2005; 86:183-193.
18. Hopkins HS, Gelenberg AJ. Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. Bipolar Disord 2000; 2:174-179.
19. Dodds G. Lithium therapy. Scott Med J 2000; 45:171-173.
20. + and other cations in the rat brain following long-term lithium administration. J Neurochem 1992; 59:1372-1380.
21. Pearce JM, Lyon M, Komoroski RA. Localized 7Li MR spectroscopy: in vivo brain and serum concentrations in the rat. Mag Reson Med 2004; 52:1087-1092.
22. Plenge P, Stensgaard A, Jensen HV, Thomsen C, Mellerup ET, Henriksen O. 24-h lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry 1994; 36:511-516.
23. Parthasarathy LK, Seelan RS, Wilson MA, Vadnal RE, Parthasarathy RN. Regional changes in rat brain inositol monophosphatase 1 (IMPase 1) activity with chronic lithium treatment. Prog Neuropsychopharmacol Biol Psychiatry 2006; 27:55-60.
24. Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005; 7:1-10.
25. Savolainen KM, Hirvonen M-R, Tarhanen J, Nelson SR, Samson FE, Pazdernik TL. Changes in cerebral inositol-1-phosphate concentrations in LiCl-treated rats: regional and strain differences. Neurochem Res 1990; 15:541-545.